Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension

Tsung-Ming Lee, Chien Chang Chen, Hsiu Nien Shen, Nen Chung Chang

研究成果: 雜誌貢獻文章同行評審

79 引文 斯高帕斯(Scopus)

摘要

PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52% from 660±352 to 1006±316 s (P
原文英語
頁(從 - 到)497-505
頁數9
期刊Clinical Science
116
發行號6
DOIs
出版狀態已發佈 - 3月 2009

ASJC Scopus subject areas

  • 醫藥 (全部)

指紋

深入研究「Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension」主題。共同形成了獨特的指紋。

引用此